[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100364198":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":57,"centralContacts":62,"locations":72,"responsibleParty":149,"collaborators":152,"id":174,"slug":175,"hasResults":176,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":176,"sex":181,"minAge":182,"maxAge":10,"enrollmentInfo":183,"targetDuration":10,"studyType":186,"phases":10,"briefSummary":187,"conditions":188,"keywords":193,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},{"fullName":5,"class":6},"University of Latvia","OTHER",[8,17,21,25,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Gastric cancer patients undergoing surgery",null,"Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management",[13,14,15,16],"Device: Breath sampling for VOC detection","Procedure: Surgery material collection for VOC headspace analysis","Diagnostic Test: Upper endoscopy","Diagnostic Test: Microbiota testing",{"label":18,"type":10,"description":19,"interventionNames":20},"Gastric cancer patients","Patients with histologically confirmed gastric cancer (adenocarcinoma)",[13,15,16],{"label":22,"type":10,"description":23,"interventionNames":24},"Control group patients without gastric cancer","Patients without gastric malignant disease according to data obtained in upper endoscopy",[13,15,16],{"label":26,"type":10,"description":27,"interventionNames":28},"Average risk population","Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer",[13,15,16],{"label":30,"type":10,"description":31,"interventionNames":32},"Patients with dyspeptic symptoms","Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)",[13,15,16],[34,41,46,53],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DEVICE","Breath sampling for VOC detection","Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy",[26,22,18,9,30],[40],"Serum, plasma sampling for group description and stratification",{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":10},"PROCEDURE","Surgery material collection for VOC headspace analysis","Only for gastric cancer patients undergoing surgery (Group 1)",[9],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"DIAGNOSTIC_TEST","Upper endoscopy","Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)",[26,22,18,9,30],[52],"Histological and microbial evaluation of biopsy samples and gastric content",{"type":47,"name":54,"description":55,"armGroupLabels":56,"otherNames":10},"Microbiota testing","Faecal and gastric contents and biopsy samples for microbiota testing",[26,22,18,9,30],[58],{"name":59,"affiliation":60,"role":61},"Hossam Haick, PhD","TECHNION, Israel Institute for Technology","PRINCIPAL_INVESTIGATOR",[63,68],{"name":64,"role":65,"phone":66,"phoneExt":10,"email":67},"Marcis Leja, MD, PhD","CONTACT","+37129497500","marcis.leja@lu.lv",{"name":69,"role":65,"phone":70,"phoneExt":10,"email":71},"Daiga Santare, MD, PhD","+37129221107","daiga.santare@lu.lv",[73,89,107,121,135],{"facility":74,"status":75,"city":76,"state":10,"zip":10,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"A.C.Camargo Cancer Center","RECRUITING","São Paulo","Brazil","BR",{"type":80,"coordinates":81},"Point",[82,83],-46.63611,-23.5475,{"lat":83,"lon":82},[86],{"name":87,"role":65,"phone":10,"phoneExt":10,"email":88},"Emmanuel Dias Neto, MD, PhD","emmanuel@accamargo.org.br",{"facility":90,"status":91,"city":92,"state":10,"zip":10,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Pontificia Universidad Catolica de Chile","NOT_YET_RECRUITING","Santiago","Chile","CL",{"type":80,"coordinates":96},[97,98],-70.64827,-33.45694,{"lat":98,"lon":97},[101,104],{"name":102,"role":65,"phone":10,"phoneExt":10,"email":103},"Robinson Gonzalez, MD, PhD","robgonza@med.puc.cl",{"name":105,"role":65,"phone":10,"phoneExt":10,"email":106},"Alejandro Corvalan, MD, PhD","corvalan01@gmail.com",{"facility":108,"status":91,"city":109,"state":10,"zip":10,"country":110,"countryCode":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Centro Javeriano de Oncología, San Ignacio University Hospital","Bogotá","Colombia","CO",{"type":80,"coordinates":113},[114,115],-74.08175,4.60971,{"lat":115,"lon":114},[118],{"name":119,"role":65,"phone":10,"phoneExt":10,"email":120},"Raul Murillo, MD, PhD","raulhmurillo@yahoo.com",{"facility":122,"status":75,"city":123,"state":10,"zip":124,"country":125,"countryCode":126,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Institute of Clinical and Preventive Medicine, University of Latvia","Riga","LV1050","Latvia","LV",{"type":80,"coordinates":128},[129,130],24.10589,56.946,{"lat":130,"lon":129},[133,134],{"name":64,"role":65,"phone":66,"phoneExt":10,"email":67},{"name":69,"role":65,"phone":70,"phoneExt":10,"email":71},{"facility":136,"status":75,"city":137,"state":10,"zip":10,"country":138,"countryCode":139,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"National Cancer Institute of Ukraine","Kiev","Ukraine","UA",{"type":80,"coordinates":141},[142,143],30.5238,50.45466,{"lat":143,"lon":142},[146],{"name":147,"role":65,"phone":10,"phoneExt":10,"email":148},"Andrii Lukashenko, MD, PhD","mail.onco@gmail.com",{"type":61,"investigatorFullName":150,"investigatorTitle":151,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marcis Leja","Director, Institute of Clinical and Preventive Medicine",[153,155,157,159,162,164,166,168,169,171,172],{"name":154,"class":6},"Technion, Israel Institute of Technology",{"name":156,"class":6},"University of Ulm",{"name":158,"class":6},"Uppsala University",{"name":160,"class":161},"JLM Innovation GmbH","UNKNOWN",{"name":163,"class":6},"Universitaet Innsbruck",{"name":165,"class":6},"Hospital Universitario San Ignacio",{"name":167,"class":6},"Universidad de Pamplona",{"name":90,"class":6},{"name":170,"class":6},"AC Camargo Cancer Center",{"name":136,"class":6},{"name":173,"class":6},"VTT Technical Research Centre of Finland","100364198","screening-of-gastric-cancer-via-breath-volatile-organic-compounds-by-hybrid-sensing-approach-100364198",false,"NCT04022109","Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach","VOGAS","Inclusion Criteria:\n\n* Patients with verified gastric cancer (Group 1 \\& 2)\n* Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \\& 5)\n* Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)\n* Motivation to participate in the study\n* Physical status allowing volatile marker sampling and other procedures within the protocol\n* Signed consent\n\nExclusion Criteria:\n\n* Known other active cancer\n* Ventilation problems, airway obstruction\n* Unwillingness or inability to co-operate","ALL","18 Years",{"count":184,"type":185},5000,"ESTIMATED","OBSERVATIONAL","The study is aimed to determine the potential of volatile marker testing for gastric cancer screening.\n\nThe study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.",[189,190,191,192],"Gastric Cancer","Atrophic Gastritis","Gastric Dysplasia","H.Pylori Infection",[194,195,196,197,198,199,200,201],"Volatile organic compounds","Breath testing","Gastric cancer","Atrophic gastritis","Precancerous lesions","Screening","Nanosensor technology","GC-MS","2021-07-19",{"date":204,"type":205},"2021-07-26","ACTUAL",{"date":207,"type":205},"2019-11-01",{"date":209,"type":185},"2026-12",{"name":5,"class":6},5]